1
John L LaMattina, Christopher A Lipinski: Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, March 6, 1984: US04435396 (12 worldwide citation)

Heretofore unavailable 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles; a novel process therefor, also advantageous for the preparation of known antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles; intermediate compounds therefor; and a method for treatment of ulcers in mam ...


2
John L La Mattina, Christopher A Lipinski: 2-Guanidino-4-heteroarylthiazoles. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, February 22, 1983: US04374843 (10 worldwide citation)

A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists ...


3
Christopher A Lipinski: Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use. Pfizer, Charles J Knuth, Albert E Frost, James M McManus, March 11, 1986: US04575507 (9 worldwide citation)

Compounds related to 3',4'-dihydrospiro[imidazolidine-4,1'(2'H)-naphthalene]2,3',5-trione, spiro[chroman-4,4'-imidazolidine]2,2',5'-trione and 1',2'-dihydrospiro[imidazolidine-4,4'-(3'H)-quinoline 2,2'5-trione and reduced products thereof as aldose reductase inhibitors.


4
Christopher A Lipinski: Spiro-heteroazalones for treatment of diabetic complications. Pfizer, Peter C Richardson, Paul H Ginsburg, Robert F Sheyka, November 19, 1991: US05066659 (8 worldwide citation)

Spiro-heteroazolones are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes. Pharmaceutical compositions containing the spiro compounds and a method of treating diabetic complications are also disclosed.


5
John L LaMattina, Christopher A Lipinski: Imidazolylpyridine therapeutic agents. Pfizer, Charles J Knuth, Peter C Richardson, James M McManus, November 24, 1981: US04302464 (6 worldwide citation)

A series of 2-substituted-4-(4-imidazolyl)pyridines and the pharmaceutically acceptable acid addition salts thereof as histamine H.sub.2 -receptor inhibitors for controlling gastric acidity.


6
Christopher A Lipinski: 5-M-Tolyloxyuracil, anti-ulcer agent. Pfizer, Connolly and Hutz, March 21, 1978: US04080454 (5 worldwide citation)

5-M-Tolyloxyuracil, in substantially pure form and also in unit dosage form in a pharmaceutically acceptable diluent. Its use in the treatment of peptic ulcer is claimed.


7
Christopher A Lipinski: Spiro-3-hetero-azolones for treatment of diabetic complications. Pfizer, Charles J Knuth, Peter C Richardson, December 3, 1985: US04556670 (2 worldwide citation)

Spiro-oxazolidones, -thiazolidones and -imidazolidones are disclosed which are useful as aldose reductase inhibitors and as therapeutic agents for the treatment of complications arising from diabetes. Pharmaceutical compositions containing the spiro compounds and a method of treating diabetic compli ...


8
John L LaMattina, Christopher A Lipinski: 2-guanidino-4-heteroarylthiazoles. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, May 20, 1986: US04590299 (2 worldwide citation)

A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists ...


9
Christopher A Lipinski: Hydroxyacetic acid derivatives for the treatment of diabetic complications. Pfizer, Peter C Richardson, J Trevor Lumb, Robert K Blackwood, August 1, 1989: US04853410 (1 worldwide citation)

Racemic and chiral (2R,4R)-4-c-hydroxy-2-4-(substituted)chroman(and thiochroman)-4-acetic acids and their pharmaceutically acceptable salts, their use in the treatment of diabetic complications and intermediates therefor.


10
Christopher A Lipinski: Pyridylaminotriazole therapeutic agents. Pfizer, Connolly and Hutz, June 30, 1981: US04276297 (1 worldwide citation)

A series of novel 3-amino-5-(4-pyridyl)-1,2,4-triazole derivatives has been prepared, including their pharmaceutically acceptable acid addition salts. These particular compounds are useful in therapy as anti-ulcer agents. Preferred member compounds include 3-amino-5-[2-(N-monomethylamino)-4-pyridyl] ...